Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer

Vernon J. Harvey , Janet R. Hardy , Shelba Smith , William Grove , Bruce C. Baguley
{"title":"Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer","authors":"Vernon J. Harvey ,&nbsp;Janet R. Hardy ,&nbsp;Shelba Smith ,&nbsp;William Grove ,&nbsp;Bruce C. Baguley","doi":"10.1016/0277-5379(91)90427-F","DOIUrl":null,"url":null,"abstract":"<div><p>CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino]-N,5-dimethyl-4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity. It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m<sup>2</sup> divided over 3 days, repeated every 3 weeks) determined by phase I trial. Patients had a median performance status of 1 (WHO), and median age of 61 years. The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1). Neutropenia grade ≥ 3 was seen in 15 patients, infections with recovery in 3, and <em>grand mal</em> seizures in 1 patient. Grade ≤ 2 nausea and vomiting occurred in 66% courses and phlebitis in the infusion arm in 37%. 1 patient with squamous cell carcinoma achieved a partial response lasting 5 months. Further testing in this and other tumour types using multiple daily schedules is warranted.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90427-F","citationCount":"17","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer and Clinical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/027753799190427F","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 17

Abstract

CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino]-N,5-dimethyl-4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity. It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial. Patients had a median performance status of 1 (WHO), and median age of 61 years. The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1). Neutropenia grade ≥ 3 was seen in 15 patients, infections with recovery in 3, and grand mal seizures in 1 patient. Grade ≤ 2 nausea and vomiting occurred in 66% courses and phlebitis in the infusion arm in 37%. 1 patient with squamous cell carcinoma achieved a partial response lasting 5 months. Further testing in this and other tumour types using multiple daily schedules is warranted.

amsacrine类似物CI-921 (NSC 343499)治疗非小细胞肺癌的II期研究
Ci-921 (nsc 343499;9-[[2-甲氧基-4-[(甲基磺酰基)氨基]苯基]氨基]- n,5-二甲基-4-吖啶甲酰胺)是一种具有高抗肿瘤活性的拓扑异构酶ⅱ类毒素。16例可评估的非小细胞肺癌(NSCLC)患者(7例未接受过治疗,9例手术/放疗后复发)通过15分钟输注给药,剂量(648 mg/m2,分3天,每3周重复一次)由I期试验确定。患者的中位表现状态为1 (WHO),中位年龄为61岁。组织学包括鳞状癌(11例)、腺癌(1例)、混合组织学(2例)、细支气管肺泡癌(1例)和大细胞未分化癌(1例)。中性粒细胞减少≥3级15例,感染恢复3例,癫痫大发作1例。66%的疗程中出现≤2级恶心和呕吐,37%的疗程中出现静脉炎。1例鳞状细胞癌患者获得了持续5个月的部分缓解。进一步的测试,在这种和其他肿瘤类型使用多个每日时间表是必要的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信